Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive muscle weakness and eventual death. Studies demonstrate that the immune system plays a key role in ALS progression; however, the role of the immune system is unclear, as various aspects can play both a beneficial and detrimental role in the disease course. Attempts to universally suppress the immune system in ALS patients have at best had negligible effects on progression or at worst accelerated the disease. Thus, there is a critical need to identify immune cell populations to serve as biomarkers and therapeutic targets.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
ALS patients (60) and matched controls (5)
Age 18 years or older.
Clinically definite, probable, probable laboratory supported, or possible ALS by El Escorial criteria
Fluency in English at the 6th grade level or higher.
Able to communicate sufficiently well by speaking
Able to communicate over the phone.
Capable of providing informed consent.
Lives geographically accessible to the University of Michigan
Unable to provide informed consent.
Clinically significant dementia, as judged by the site investigator.
Other neurological or psychiatric disorders which are expected to impair cognitive function.
Other serious and uncontrolled medical disorders.
History of autoimmune disease.
Use of prednisone, IVIG, or immunosuppression within the last 12 months.
Not geographically accessible to the University of Michigan